New trends in the cyber and street market of recreational drugs? The case of 2C-T-7 ('Blue Mystic').

The compound 2C-T-7 ('Blue Mystic'), which resembles MDMA and other designer drugs, has rarely been identified in the EU, yet online discussion among experimenters has recently grown. A review of cyber and street market information found that 2C-T-7 was first synthesized in 1986 and produces desired effects of empathy and well-being, with anecdotal reports of hallucinations, nausea, anxiety, panic attacks, and paranoid ideation. Street-level availability in Europe appears very low, though one US death from mono-intoxication is documented. From an initial 360 websites, 118 were analyzed: 14 (11.9%) described synthesis, and 5 (4.2%) offered the drug for sale.

Study at a glance

Abstract

2C-T-7 ('Blue Mystic'), an illicit compound which shows similarities with MDMA and other designer drugs, has been only occasionally identified in the EU, but discussion on the Internet between experimenters has recently grown significantly. We aimed at collecting together in a review the available information on 2C-T-7, both at the cyber and at the street market level. 2C-T-7 was first synthesized in 1986; its desired effects include both a sense of empathy and of well-being. Hallucinations, nausea, anxiety, panic attacks and paranoid ideation are anecdotally reported. According to the different European sources here approached, the availability of 2C-T-7 at street level seems to be currently very low, although one death related to a mono-intoxication with 2C-T-7 has been documented in the USA. With respect to information on 2C-T-7 available online, due to both redundancy and relevance issues the initial identified sample of 360 was reduced to 118 websites. In 14 (11.9%) websites, the detailed description of the 2C-T-7 synthesis was given. Harm Reduction websites appeared significantly earlier in the search engines results' list than Anti drugs (p 0.006) websites. Five (4.2%) websites apparently offered 2C-T-7 for sale. The large body of knowledge available online seems to contrast with small numbers of seizures at street level; an exhaustive web mapping of drug-related issues may be of interest for the clinician. Projects aimed at designing more 'attractive' prevention websites should be planned and future studies should better assess the characteristics of those consumers who take advantage of the online information of hallucinogenic compounds.